# TIE2 receptor (TEK)

Source: https://onco.cc/targets/tie2/  
OnCo record `tie2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TIE2 is the angiopoietin receptor that keeps blood vessels stable; regorafenib and cabozantinib block it as part of their attack on the tumour's blood supply.

## Summary

TEK (TIE2) is the receptor for angiopoietins 1 and 2 on endothelial cells and a subset of macrophages, controlling vessel maturation and remodelling. Regorafenib and cabozantinib inhibit TIE2 alongside VEGF receptors, and the angiopoietin-2 antibody trebananib was tested in ovarian cancer without approval. TIE2-expressing macrophages are a source of resistance to anti-VEGF therapy.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: TEK
- Class: kinase
- Biology: A receptor tyrosine kinase activated by angiopoietin-1 and antagonised or weakly activated by angiopoietin-2, signalling through AKT to stabilise the endothelium.
- Where found: Tumour and normal endothelium; TIE2-expressing monocytes and macrophages

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/TEK_tyrosine_kinase
- UniProt Q02763: TEK: https://www.uniprot.org/uniprotkb/Q02763/entry
- HGNC:11724 TEK: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11724
- ChEMBL target CHEMBL4128: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4128

## Connected records

- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Angiogenesis](https://onco.cc/terms/angiogenesis/)

---
JSON: https://onco.cc/api/v1/entities/tie2.json